Overview Dividends

(ASND) Ascendis Pharma AS - Ratings and Ratios

Exchange: NASDAQ • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US04351P1012

Growth Hormone, Hypoparathyroidism, Endocrinology, Oncology, Rare Disease

ASND EPS (Earnings per Share)

EPS Growth (3Y CAGR): 202.56%
EPS Trend (3Y Correlation): 82.9%

ASND Revenue

Revenue Growth (3Y CAGR): 133.81%
Revenue Trend (3Y Correlation): 81.0%

Risk via 10d forecast
Volatility	37.2%
Value at Risk 5%th	53.9%

Reward
Sharpe Ratio	1.28
Alpha Jensen	49.44

Character
Hurst Exponent	0.495
Beta	0.448

Drawdowns 3y
Max DD	44.82%
Mean DD	13.69%

Description: ASND Ascendis Pharma AS October 30, 2025

Ascendis Pharma A/S (NASDAQ: ASND) is a Denmark-based biopharmaceutical firm that commercializes its proprietary TransCon technology platform to create long-acting prodrugs for endocrine and oncology indications. The company’s two marketed products are SKYTROFA™ (a TransCon growth-hormone for pediatric growth-hormone deficiency) and YORVIPATH™ (a once-daily TransCon-parathyroid hormone for adult chronic hypoparathyroidism), both of which have received approvals in the United States and the European Union.

Beyond the two approved therapies, Ascendis is advancing three rare-endocrinology candidates-targeting X-linked hypophosphatemia, hypophosphatasia, and another parathyroid-related disorder-through Phase 2/3 trials, while its oncology pipeline includes a TransCon-estrogen receptor degrader in early-stage development. As of Q3 2024, the company reported approximately $55 million in SKYTROFA sales and $12 million in YORVIPATH revenue, with a cash balance of $340 million, giving it an estimated 18-month runway without additional financing.

Sector-wide, the global rare-disease therapeutics market is projected to grow at a 12% compound annual growth rate through 2030, driven by higher payer willingness to fund high-value, disease-modifying treatments-an environment that could amplify Ascendis’s upside if its pipeline clears pivotal trials. For investors seeking a data-rich, unbiased deep-dive into Ascendis’s risk-adjusted valuation, a look at ValueRay’s analyst toolkit may uncover the granular metrics needed to form a disciplined view.

ASND Stock Overview

Market Cap in USD	11,974m
Sub-Industry	Biotechnology
IPO / Inception	2015-01-28
Return 12m vs S&P 500	35.7%
Analyst Rating	4.75 of 5

ASND Dividends

Currently no dividends paid

ASND Growth Ratios

CAGR	22.46%
CAGR/Max DD Calmar Ratio	0.50
CAGR/Mean DD Pain Ratio	1.64
Current Volume	519.1k
Average Volume	366.3k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-271.1m TTM) > 0 and > 6% of Revenue (6% = 29.4m TTM)

FCFTA -0.16 (>2.0%) and ΔFCFTA 28.01pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 3.66% (prev -69.39%; Δ 73.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.15 (>3.0%) and CFO -165.0m > Net Income -271.1m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (63.9m) change vs 12m ago 11.45% (target <= -2.0% for YES)

Gross Margin 84.88% (prev 85.56%; Δ -0.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 53.16% (prev 41.89%; Δ 11.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -1.04 (EBITDA TTM -150.9m / Interest Expense TTM 159.8m) >= 6 (WARN >= 3)

Altman Z'' -11.28

(A) 0.02 = (Total Current Assets 953.0m - Total Current Liabilities 935.0m) / Total Assets 1.09b

(B) -2.45 = Retained Earnings (Balance) -2.67b / Total Assets 1.09b

warn (B) unusual magnitude: -2.45 — check mapping/units

(D) -2.08 = Book Value of Equity -2.66b / Total Liabilities 1.28b

Total Rating: -11.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.92

1. Piotroski 1.0pt = -4.0

2. FCF Yield -1.60% = -0.80

3. FCF Margin -34.82% = -7.50

4. Debt/Equity -4.23 = -2.50

5. Debt/Ebitda -1.98 = -2.50

6. ROIC - WACC (= -34.70)% = -12.50

7. RoE 186.9% = 2.50

8. Rev. Trend 80.98% = 6.07

9. EPS Trend 82.92% = 4.15

What is the price of ASND shares?

As of November 12, 2025, the stock is trading at USD 201.16 with a total of 519,088 shares traded.
Over the past week, the price has changed by -3.40%, over one month by -3.49%, over three months by +2.65% and over the past year by +56.67%.

Is Ascendis Pharma AS a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Ascendis Pharma AS (NASDAQ:ASND) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 32.92 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ASND is around 209.52 USD . This means that ASND is currently overvalued and has a potential downside of 4.16%.

Is ASND a buy, sell or hold?

Ascendis Pharma AS has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy ASND.

Strong Buy: 12
Buy: 4
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ASND price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	250.7	24.6%
Analysts Target Price	250.7	24.6%
ValueRay Target Price	231.4	15%

ASND Fundamental Data Overview November 11, 2025

Market Cap EUR = 10.36b (11.97b USD * 0.865 USD.EUR)
P/E Forward = 43.8596
P/S = 24.3996
P/B = 14.5547
Beta = 0.448
Revenue TTM = 490.7m EUR
EBIT TTM = -166.0m EUR
EBITDA TTM = -150.9m EUR
Long Term Debt = 330.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 462.3m EUR (from shortTermDebt, last quarter)
Debt = 792.5m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 298.5m EUR (from netDebt column, last quarter)
Enterprise Value = 10.66b EUR (10.36b + Debt 792.5m - CCE 494.0m)
Interest Coverage Ratio = -1.04 (Ebit TTM -166.0m / Interest Expense TTM 159.8m)
FCF Yield = -1.60% (FCF TTM -170.9m / Enterprise Value 10.66b)
FCF Margin = -34.82% (FCF TTM -170.9m / Revenue TTM 490.7m)
Net Margin = -55.25% (Net Income TTM -271.1m / Revenue TTM 490.7m)
Gross Margin = 84.88% ((Revenue TTM 490.7m - Cost of Revenue TTM 74.2m) / Revenue TTM)
Gross Margin QoQ = 80.10% (prev 82.65%)
Tobins Q-Ratio = 9.80 (Enterprise Value 10.66b / Total Assets 1.09b)
Interest Expense / Debt = 4.17% (Interest Expense 33.0m / Debt 792.5m)
Taxrate = -10.99% (negative due to tax credits) (3.85m / -35.0m)
NOPAT = -184.2m (EBIT -166.0m * (1 - -10.99%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.02 (Total Current Assets 953.0m / Total Current Liabilities 935.0m)
Debt / Equity = -4.23 (negative equity) (Debt 792.5m / totalStockholderEquity, last quarter -187.6m)
Debt / EBITDA = -1.98 (negative EBITDA) (Net Debt 298.5m / EBITDA -150.9m)
Debt / FCF = -1.75 (negative FCF - burning cash) (Net Debt 298.5m / FCF TTM -170.9m)
Total Stockholder Equity = -145.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.92% (Net Income -271.1m / Total Assets 1.09b)
RoE = 186.9% (negative equity) (Net Income TTM -271.1m / Total Stockholder Equity -145.1m)
RoCE = -89.67% (EBIT -166.0m / Capital Employed (Equity -145.1m + L.T.Debt 330.2m))
RoIC = -27.24% (negative operating profit) (NOPAT -184.2m / Invested Capital 676.2m)
WACC = 7.45% (E(10.36b)/V(11.15b) * Re(7.67%) + D(792.5m)/V(11.15b) * Rd(4.17%) * (1-Tc(-0.11)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 6.25%
Fair Price DCF = unknown (Cash Flow -170.9m)
EPS Correlation: 82.92 | EPS CAGR: 202.6% | SUE: 0.52 | # QB: 0
Revenue Correlation: 80.98 | Revenue CAGR: 133.8% | SUE: 0.12 | # QB: 0

Additional Sources for ASND Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle